Novartis works with Bill & Melinda Gates Foundation on diarrhoeal disease therapy

Novartis has joined forces with the Bill & Melinda Gates Foundation to develop new treatments for infectious diarrhoeal disease.

The pharmaceutical firm wants to advance the progress of its drug candidate KDU731 for treating cryptosporidiosis, as it is the second-leading cause of infectious diarrhoea in children.

To support this work, the Bill & Melinda Gates Foundation is donating USD 6.5 million to the Novartis Institute for Tropical Diseases (NITD).

Thierry Diagana, head of NITD, commented: "We are committed to the fight against cryptosporidiosis and other infectious and neglected tropical diseases and are proud to work closely with the Bill & Melinda Gates Foundation and other partners in this effort."

However, he stressed that today's global health issues cannot be solved by a single organisation alone. 

This, he said, means private companies, governments, non-governmental organisations, academics and other stakeholders must work together to create sustainable solutions.

According to figures from Novartis, diarrhoeal diseases are responsible for about 525,000 child deaths around the world every year.
 
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.